Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Dig Dis Sci ; 65(2): 576-580, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31093812

RESUMO

BACKGROUND: Patients admitted to hospital with acute severe ulcerative colitis have a short-term in-hospital colectomy rate of 30%. The Oxford criteria state that if the CRP is greater than 45 mg/l or there are more than eight bowel movements in 24 h at day 3 of intravenous corticosteroids, there is an 85% risk of an in-hospital colectomy. AIM: The aim of this study was to determine whether this high rate of colectomy continues to be accurate in this medically refractory patient population. METHODS: We performed a retrospective chart review of 80 patients admitted to a tertiary hospital between 2013 and 2017 with acute severe ulcerative colitis. RESULTS: Sixteen (20%) patients required an in-hospital colectomy. Of the 33 patients that fulfilled the Oxford criteria, 12 (36%) patients required a colectomy during admission. Only four (9.5%) patients who did not fulfill the Oxford criteria required a colectomy during admission. Twenty-two patients that had fulfilled the Oxford criteria received infliximab as second-line medical therapy. CONCLUSION: In a patient population that fulfilled the Oxford criteria, the in-hospital colectomy rate has reduced from 85% in 1996 to 36% in 2017. These results should be considered when discussing with patients the opportunity to commence infliximab or cyclosporine as second-line medical therapy.


Assuntos
Colectomia/estatística & dados numéricos , Colite Ulcerativa/terapia , Ciclosporina/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Glucocorticoides/uso terapêutico , Infliximab/uso terapêutico , Doença Aguda , Administração Intravenosa , Adulto , Proteína C-Reativa/metabolismo , Colite Ulcerativa/metabolismo , Defecação , Feminino , Hospitalização , Humanos , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Medição de Risco , Índice de Gravidade de Doença , Resultado do Tratamento
2.
Inflamm Bowel Dis ; 25(6): 1107-1114, 2019 05 04.
Artigo em Inglês | MEDLINE | ID: mdl-30535387

RESUMO

BACKGROUND: Fecal calprotectin (FC) is a stool biomarker that has been shown to be sensitive and specific for mucosal inflammation in patients with inflammatory bowel disease (IBD). The test is limited by the requirement for patients to collect and return stool samples. A home-based FC test may improve test adherence. The aim of this study is to evaluate the usability of the IBDoc, a home-based FC measuring test, and to determine the accuracy of results compared with traditional lab-based ELISA values. METHODS: Patients were prospectively enrolled from 3 tertiary sites across Canada between May and August 2017. Patients completed a questionnaire establishing ease-of-use of the IBDoc. Patients completed a FC measurement using the IBDoc, and results were compared with an ELISA-determined FC measurement on the same stool sample. RESULTS: Sixty-one participants were enrolled in the study (29 CD, 32 UC). Seventy-nine percent of patients (48 of 61) agreed that the IBDoc was easy to use, with 85% (52 of 61) of patients strongly agreeing that they were willing use the home kit in the future. The IBDoc and ELISA measurement comparison showed an 88% agreement across all values. There were no false positives or negatives using qualitative comparison. CONCLUSIONS: The home-based IBDoc FC measuring test is acceptable to patients and correlates extremely well with the standard ELISA-determined FC value. The IBDoc enables clinicians to more easily adopt a treat-to-target approach, improve long-term outcomes, and patients' quality of life with IBD. This study is registered at ClinicalTrials.gov, number NCT03408249.


Assuntos
Biomarcadores/análise , Fezes/química , Inflamação/diagnóstico , Doenças Inflamatórias Intestinais/diagnóstico , Complexo Antígeno L1 Leucocitário/análise , Qualidade de Vida , Autoexame/métodos , Adulto , Canadá , Ensaio de Imunoadsorção Enzimática , Feminino , Seguimentos , Humanos , Inflamação/complicações , Doenças Inflamatórias Intestinais/complicações , Masculino , Prognóstico , Estudos Prospectivos , Índice de Gravidade de Doença , Inquéritos e Questionários
3.
J R Army Med Corps ; 162(6): 434-439, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26036822

RESUMO

BACKGROUND: Heat illness is a preventable disorder in military populations. Measures that protect vulnerable individuals and contribute to effective Immediate Treatment may reduce the impact of heat illness, but depend upon adequate understanding and awareness among Commanders and their troops. OBJECTIVE: To assess risk factors for heat illness in British soldiers deployed to the hot Collective Training Environment (CTE) and to explore awareness of Immediate Treatment responses. METHODS: An anonymous questionnaire was distributed to British soldiers deployed in the hot CTEs of Kenya and Canada. Responses were analysed to determine the prevalence of individual (Intrinsic) and Command-practice (Extrinsic) risk factors for heat illness and the self-reported awareness of key Immediate Treatment priorities (recognition, first aid and casualty evacuation). RESULTS: The prevalence of Intrinsic risk factors was relatively low in comparison with Extrinsic risk factors. The majority of respondents were aware of key Immediate Treatment responses. The most frequently reported factors in each domain were increased risk by body composition scoring, inadequate time for heat acclimatisation and insufficient briefing about casualty evacuation. CONCLUSIONS: Novel data on the distribution and scale of risk factors for heat illness are presented. A collective approach to risk reduction by the accumulation of 'marginal gains' is proposed for the UK military. This should focus on limiting Intrinsic risk factors before deployment, reducing Extrinsic factors during training and promoting timely Immediate Treatment responses within the hot CTE.


Assuntos
Aclimatação , Composição Corporal , Transtornos de Estresse por Calor/epidemiologia , Militares , Aptidão Física , Antagonistas Adrenérgicos beta/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Canadá/epidemiologia , Desidratação/epidemiologia , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , Fome , Quênia/epidemiologia , Prevalência , Fatores de Risco , Privação do Sono/epidemiologia , Inquéritos e Questionários , Reino Unido/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA